Key Highlights

  • Loss per share of USD 1.28 was wider than the USD 1.15 consensus estimate and USD 1.10 a year ago.
  • Revenue of USD 0.3 million fell short of the USD 8.75 million consensus estimate and USD 9.7 million last year.
  • Net loss widened to USD 134.4 million from USD 112.6 million as general and administrative expense rose 18%.
  • Cash, equivalents and marketable securities totaled USD 1.04 billion, down from USD 1.25 billion at year end 2025.

Beam Therapeutics Inc. (NASDAQ:BEAM) reported a third quarter 2026 net loss of USD 134.4 million, or USD 1.28 per share, compared with a net loss of USD 112.6 million, or USD 1.10 per share, a year earlier. The loss per share was wider than a consensus estimate of a USD 1.15 loss. License and collaboration Revenue of USD 0.3 million trailed a consensus estimate of USD 8.75 million and the USD 9.7 million recorded in the prior year quarter, a USD 9.4 million decrease the company tied to the level of research activity on its license and collaboration programs.

Expense Mix and Other Income Swings

Research and development expense was nearly flat at USD 110.1 million versus USD 109.8 million, but the composition shifted. Other Research and Development costs rose USD 15.9 million to USD 16.6 million on milestone activity, employee related costs rose USD 4.6 million as research headcount grew to 429 from 397, and in-process research and development expense of USD 14.5 million in the prior year did not recur. General and administrative expense rose USD 4.8 million to USD 31.5 million, with headcount at 128 versus 113. Loss from operations widened to USD 141.3 million from USD 126.8 million. Interest and other income fell to USD 6.1 million from USD 10.9 million, and a USD 4.7 million gain on derivative liabilities was offset by changes in contingent consideration and Equity Investment values. Nine month net loss reached USD 351.4 million, or USD 3.38 per share, versus USD 323.0 million, or USD 3.31.

Pipeline Status and Financing Arrangements

For risto-cel in sickle cell disease, dosing is complete for all patients in the BEACON trial of about 50 adults and adolescents, and the company plans to report updated data by year end 2026 and to submit a Biologics license application as early as year end 2026. For BEAM-302 in alpha-1 antitrypsin deficiency, 38 patients had been treated as of August 17, 2026, and updated safety and efficacy data were announced in September. In February 2026 the company entered a Credit Facility with an initial draw of USD 100.0 million, up to USD 300 million tied to risto-cel milestones and a further USD 100 million at its option. The facility matures on February 24, 2033 and bears interest at the 3-month SOFR plus 6.5%, subject to a 1.00% floor.

Cash and Capital Sources Against Year End 2025

Cash, cash equivalents and marketable securities of USD 1,043.9 million compare with USD 1,245.2 million at December 31, 2025, a decline of USD 201.3 million. Long Term Debt stands at USD 100.4 million against none at year end, and total liabilities were USD 316.4 million versus USD 242.8 million. The company sold no shares under its USD 1.1 billion at-the-market program in 2026, having sold USD 864.0 million gross to date. Management said current resources fund planned operating expenses and capital expenditures for at least the next 12 months. Success payments of up to USD 90.0 million each may be owed to Harvard and the Broad Institute.